Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Efficacy and Safety of Novel Oral Anticoagulants in Patients with Cervical Artery Dissections
We report on the use, safety, and efficacy of NOACs in the treatment of CAD. Methods: We retrospectively identified patients diagnosed with CAD at a single academic center between January 2010 and August 2013. Patients were categorized by their antithrombotic treatment at hospital discharge with a NOAC (dabigatran, rivaroxaban, or apixaban), traditional anticoagulant (AC: warfarin or treatment dose low-molecular weight heparin), or antiplatelet agent (AP: aspirin, clopidogrel, or aspirin/extended-release dypyridamole). Using appropriate tests, we compared the baseline medical history, presenting clinical symptoms and initi...
Source: Cerebrovascular Diseases - November 12, 2014 Category: Neurology Source Type: research

Postoperative warfarin following mitral valve repair or bioprosthetic valve replacement.
CONCLUSION: The use of postoperative warfarin following MVR does not reduce the incidence of stroke at early follow up. However, there remains a trend for improved long-term outcomes in those patients receiving postoperative warfarin therapy. PMID: 24383387 [PubMed - indexed for MEDLINE]
Source: Journal of Heart Valve Disease - December 1, 2014 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland
Conclusions In this large prospective ACS cohort, patients treated with prasugrel according to current guidelines (ie, in patients without cerebrovascular disease, old age or underweight) had a similar safety profile compared with patients treated with clopidogrel. Clinical trial registration number SPUM-ACS: NCT01000701; COMFORTABLE AMI: NCT00962416.
Source: Heart - May 12, 2015 Category: Cardiology Authors: Klingenberg, R., Heg, D., Raber, L., Carballo, D., Nanchen, D., Gencer, B., Auer, R., Jaguszewski, M., Stahli, B. E., Jakob, P., Templin, C., Stefanini, G. G., Meier, B., Vogt, P., Roffi, M., Maier, W., Landmesser, U., Rodondi, N., Mach, F., Windecker, S. Tags: Drugs: cardiovascular system, Acute coronary syndromes, Epidemiology Coronary artery disease Source Type: research

Complications and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement With Edwards SAPIEN & SAPIEN XT Valves: A Meta‐Analysis of World‐Wide Studies and Registries Comparing the Transapical and Transfemoral Accesses
ConclusionThis meta‐analysis demonstrates a decreased 30‐day and 1‐year mortality in TF TAVR as compared to TA TAVR. Post‐procedure acute kidney injury and the need for renal replacement therapy are also significantly lower in the TF group. These differences hold true even after utilizing the standardized Valve Academic Research Consortium criteria.
Source: Journal of Interventional Cardiology - May 20, 2015 Category: Cardiology Authors: Abhijit Ghatak, Chirag Bavishi, Rhanderson N. Cardoso, Conrad Macon, Vikas Singh, Apurva O. Badheka, Santosh Padala, Mauricio G. Cohen, Raul Mitrani, William O'Neill, Eduardo De Marchena Tags: Original Investigation Source Type: research

Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
CONCLUSION: This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary PCI strategy. The observed rates of major outcomes were similar, although with broad confidence intervals around the estimates. These interesting observations need to be confirmed in a larger trial. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT02808767. PMID: 27576777 [PubMed - as supplied by publisher]
Source: Circulation - August 29, 2016 Category: Cardiology Authors: Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J, Knot J, Jarkovsky J, Kala P, Rokyta R, Tousek F, Kramarikova P, Majtan B, Simek S, Branny M, Mrozek J, Cervinka P, Ostransky J, Widimsky P Tags: Circulation Source Type: research

Comparative Matched Outcome of Evolut-R vs CoreValve Transcatheter Aortic Valve Implantation.
CONCLUSION: This study indicates that the efficacy and safety of the self-expandable second-generation Evolut-R transcatheter valve is at least comparable with the first-generation CoreValve. The observed improved performance in correct positioning of a single valve and the numerically lower chance to suffer a combined TAVI endpoint needs further investigation. PMID: 28145874 [PubMed - in process]
Source: The Journal of Invasive Cardiology - February 3, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Systemic Thrombolysis, Catheter ‐Directed Thrombolysis and Anticoagulation for Intermediate‐Risk Pulmonary Embolism: A Simulation Modeling Analysis
ConclusionIn our model, for those eligible, CDT results in the largest number of QALYs for patients with intermediate‐risk PE, although it is relatively expensive and the absolute difference in QALYs between anticoagulation alone and CDT is small. Future studies that provide data on longitudinal quality‐of‐life outcomes of patients treated for PE and characteristics of CDT would be beneficial to augment model inputs, inform assumptions, and validate results.This article is protected by copyright. All rights reserved.
Source: Academic Emergency Medicine - June 26, 2017 Category: Emergency Medicine Authors: Christopher Kabrhel, Ayman Ali, Jin Choi, Chin Hur Tags: Original Contribution Source Type: research

Outcome of transcatheter aortic valve implantation in high risk patients with severe aortic stenosis
Conclusion TAVI is a safe and effective procedure in selected high-risk patients with severe symptomatic aortic stenosis without significant difference between used valves.
Source: The Egyptian Heart Journal - August 7, 2017 Category: Cardiology Source Type: research

Head ‐to‐head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials
ConclusionsAlthough the efficacy was similar between prasugrel and ticagrelor, prasugrel may be associated with a lower risk of bleeding compared with ticagrelor during short‐ to mid‐term follow‐up period after PCI. Further studies are warranted in a larger patient population during longer‐term follow up to validate these findings.
Source: Journal of Interventional Cardiology - August 1, 2017 Category: Cardiology Authors: Ryota Sakurai, Ivana Burazor, Heidi N. Bonneau, Hideaki Kaneda Tags: ORIGINAL INVESTIGATION Source Type: research

Atrial Fibrillation Decision Support Tool: Population Perspective
Conclusions Availability of DOACs increases the proportion of patients for whom oral anticoagulation therapy is recommended in a real-world cohort of AF patients and increased projected QALYs by more than 1500 when all patients are receiving thromboprophylaxis as recommended by the AFDST compared with current treatment.
Source: American Heart Journal - August 23, 2017 Category: Cardiology Source Type: research

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT01959451, and EudraCT, 2013-001636-22. Findings Between Dec 2, 2013, and May 20, 2016, 2610 patients were assigned to study groups; 1304 to the guided de-escalation group and 1306 to the control group. The primary endpoint occurred in 95 patients (7%) in the guided de-escalation group and in 118 patients (9%) in the control group (pnon-inferiority=0·0004; hazard ratio [HR] 0·81 [95% CI 0·62–1·06], psuperiority=0·12). Despite early de-escalation, there was no increase in the combined risk of cardiovascular death, myocardial infarction, or stroke in the de-es...
Source: The Lancet - August 29, 2017 Category: General Medicine Source Type: research

Systemic Thrombolysis, Catheter ‐Directed Thrombolysis, and Anticoagulation for Intermediate‐risk Pulmonary Embolism: A Simulation Modeling Analysis
ConclusionIn our model, for those eligible, CDT results in the largest number of QALYs for patients with intermediate‐risk PE, although it is relatively expensive and the absolute difference in QALYs between anticoagulation alone and CDT is small. Future studies that provide data on longitudinal quality‐of‐life outcomes of patients treated for PE and characteristics of CDT would be beneficial to augment model inputs, inform assumptions, and validate results.
Source: Academic Emergency Medicine - September 13, 2017 Category: Emergency Medicine Authors: Christopher Kabrhel, Ayman Ali, Jin G. Choi, Chin Hur Tags: Original Contribution Source Type: research

Single versus dual anti-platelet therapy post transcatheter aortic valve implantation: a meta-analysis of randomized controlled trials
In conclusion, SAPT provided similar safety without adding incremental efficacy compared to DAPT but showed tendency of lower combined endpoints of 30-day mortality, life-threatening and major bleeding.
Source: Journal of Thrombosis and Thrombolysis - September 13, 2017 Category: Hematology Source Type: research

Anticoagulation prescribing patterns in patients with cancer
The objective of this retrospective cohort was to describe real-world anticoagulation prescribing patterns in cancer patients at a large academic medical center between January 1, 2013 and October 31, 2016. We sought to assess the safety, tolerability, and efficacy of DOACs in patients with cancer for either VTE and/or AF. Patient demographic, clinical characteristics, as well as bleeding and thrombotic events were collected. There were 214 patients in our analysis, of which 71 patients (33%) received a DOAC [apixaban (n  = 22), dabigatran (n = 17), and rivaroxaban (n = 32)]. There were fewer bleeding events an...
Source: Journal of Thrombosis and Thrombolysis - October 19, 2017 Category: Hematology Source Type: research

Thirty-Day Outcomes in 100 Consecutive Patients Undergoing Transfemoral Aortic Valve Replacement With the Portico Valve on an All-Comer Basis.
CONCLUSIONS: Our immediate and 30-day post-TAVR results support favorable survival comparable to other studies, and significant clinical improvement with the Portico valve in non-selected patients in a real-world setting, with short-term complications being uncommon. PMID: 29207365 [PubMed - in process]
Source: The Journal of Invasive Cardiology - December 6, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research